VBI Vaccines Inc
OTC:VBIVQ
Operating Margin
VBI Vaccines Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
VBI Vaccines Inc
NASDAQ:VBIV
|
631k USD |
-767%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.3B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.6B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135.1B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.3B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.2B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD |
-5%
|
VBI Vaccines Inc
Glance View
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2001-11-19. The firm develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers including glioblastoma (GBM). Its PreHevbrio (Hepatitis B Vaccine [Recombinant]), which contains S, pre-S2, and pre-S1 HBV surface antigens and is an approved 3-antigen HBV vaccine for adults. Its Prophylactic candidates include VBI-2900, which is a coronavirus vaccine Program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901, which targets CMV proteins present in tumor cells. The firm is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on VBI Vaccines Inc's most recent financial statements, the company has Operating Margin of -767.1%.
You don't have any saved screeners yet